Oncology Flashcards
Bleomycin
Lifetime cumulative dose: 400 units–> pulmonary toxicity
Doxorubicin
lifetime cumulative dose: 450-550mg/m2–> cardiotoxicity
Cisplatin
dose per cycle not to exceed 100mg/m2–> nephrotoxicity
vincristine
single dose “capped” at 2mg–> neuropathy
Drugs that commonly cause myelosuppression
Almost all except: Asparaginase, bleomycin, vincristine
Drugs that commonly cause nausea/vomiting
Cisplatin, cyclophosphamide, ifosfamide
Drugs that commonly cause Mucositis
Fluorouracil and methotrexate
Drugs that commonly cause Diarrhea
Irinotecan, capecitabine, fluorouracil, and methotrexate
Drugs that commonly cause constipation
Vincristine
Common causes of Xerostomia
Caused by radiation to the head or neck region
Drugs that commonly cause cardio toxicity
Cardio myopathy: Anthrcyclines
QT prolongation: arsenic, trioxide, many TKIs
Drugs that commonly cause pulmonary toxicity
Pulmonary fibrosis: bleomycin, busulfan, carmustine, lomustine
Pneumonitis:methotrexate and MABs
Drugs that commonly cause hepatotoxicity
Antiandrogens (bicalutamide, flutamide, nilutamide)
Drugs that commonly cause nephrotoxicity
Cisplatin and methotrexate (in high doses)
Drugs that commonly cause hemorrhagic cystitis
Ifosfamide (all doses) cyclophosphamide (higher doses)
Drugs that commonly cause neuropathy
Peripheral neuropathy:
Vinca alkaloids (vincristine, vinblastine, vinorelbine)
platinums (cisplatin, oxaliplatin)
Taxanes (paclitaxel, docetaxel, cabazitaxel)
Autonomic neuropathy: Vinca alkaloids
Drugs that commonly cause thromboembolic risks
Aromatase inhibitors (anastrazole and letrazole), SERMs (tamoxifen, raloxifene
Screening for breast cancer
Female age 40-44yrs–> screening optional
45-54yrs–> yearly mammograms
55 and older–> mammograms every 2 years and annually
Screening for Cervical cancer
Female age 21-29–> PAP every 3 yrs
30-65–> PAP and HPV test every 5 yrs
Screening for Colon cancer
Males and females age 45 and older–> colonoscopy every 10 yrs
screening for lung cancer
Males and females 55-74 CT scan of chest if all of the following: in good health, have at least a 30ppy smoking history, and still smoking or quit within the past 15 years
Screening for prostate cancer
Males 50 and older if the patient opts to be tested it involves: Prostate specific antigen (PSA) test +/- a digital rectal exam (DRE)
Management of myelosuppression
- Neutropenia: colony-stimulating factors (CSFs)
- Anemia: RBC-transfusions and ESAs (in palliation only)
- thrombocytopenia: platelet transfusions (when very low, especially when bleeding
Management of N/V
- Neurokinin-1 receptor antagonist (NK1-RA)
- serotonin-3 receptor antagonist (5HT3-RA)
- dexamethasone
- IV/PO fluids hydration
management of mucositis
symptomatic treatment (lidocaine viscous)
Management of diarrhea
- IV/PO fluid hydration, antimotility agents (loperamide)
- irinotecan: atropine for early onset diarrhea
Management of constipation
stimulant laxatives: (PEG 3350 and Miralax)
Management of Xerostomia
artificial saliva substitutes, pilocarpine
management of cardio toxicity
Do not exceed recommended lifetime cumulative dose of 450-550 for doxorubicin. give dexrazoxane prophylactically in certain patients getting doxorubicin
management of pulmonary toxicities
symptomatic management, stop therapy, or corticosteroids
management of hepatotoxicity
symptomatic management, stop therapy, or corticosteroids if an auto immune mechanisms for PD-1 immunotherapy agents
management of nephrotoxicity
Amifostine (ethyol) can be given prophylactically with Cisplatin, ensure adequate hydration do not exeeed max Cisplatin dose of 100mg/m2/cycle
management of hemorrhagic cystitis
Mesna is always given prophylactically with ifosfamide and sometimes with cyclophosphamide to reduce the risk of hemorrhagic cystitits; always ensure adequate hydration
management of neuropathy
systematic treatment with drugs for neuropathic pain.
Vincristine: recommended to limit dose to 2mg per week
Oxaliplatin: causes an acute cold-mediated sensory neuropathy–> avoid cold temps and beverages
Bortezomib: SC is associated with less neuropathy than IV
management of thromboembolic risk
Consider thromboembolic prophylaxis based on pt risk factors